Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, announced that the U.S. Food and Drug Administration (FDA) has approved DAXXIFY™ (DaxibotulinumtoxinA-lanm) for injection for the

This content is restricted to registered user. If you are an existing user, please log in. New users may register for free.

New User Registration
 
 
 
 
 
 
Please indicate that you agree to the Terms of Service *
*Required field